Brief: Incyte Announces The European Commission Approval Of Zynyz® (retifanlimab) For The First-Line Treatment Of Advanced Squamous Cell Carcinoma Of The Anal Canal (SCAC)
06/03/2026 21:56
March 6 (Reuters) - Incyte Corp INCY.O: INCYTE ANNOUNCES THE EUROPEAN COMMISSION APPROVAL OF ZYNYZ® (RETIFANLIMAB) FOR THE FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL (SCAC) Source text: ID:nBwbJQq53a Further company coverage: INCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler